News
BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately ...
Veranova is pleased to announce the appointment of Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides. Dr ...
Market SynopsisThe Global In-vitro Lung Model Market is valued at USD 0.71 billion in 2024 and is projected to reach a value ...
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS RegionsEr-Kim will distribute KIMMTRAK® (tebentafusp) for the treatment of ...
Microbot Medical® Added to the Russell Microcap® IndexAutomatic inclusion in the appropriate growth and value style indexesHINGHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc.
The GOAT Collection features game-worn memorabilia from Michael Jordan, LeBron James, and Kobe Bryant; The Grail Collection to follow with high value assets from sports history's most iconic legends.
Alliance/Market LaunchBio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa 01.07.2025 / 13:15 CET/CESTThe issuer is solely responsible for ...
Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® ...
PALO ALTO, CA / ACCESS Newswire / July 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180" or the "Company), an innovative biotechnology company that is currently pivoting to the global iGaming ...
The Dark Genome Therapeutics market, valued at USD 2,155.7 million in 2024, is expected to register robust revenue CAGR of 23.8%.Request free copy of this report: 01, 2025 - Integration of AI and ...
Following positive opinion, Carthera is one of the first companies to benefit from brand-new status – intended to support early access pathways for innovative devices targeting rare diseasesParis, ...
FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results